Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 13/20 | 0.49 |
| ▸ | CA1 | P00915 | 12/20 | 0.49 |
| ▸ | CA12 | O43570 | 6/20 | 0.49 |
| ▸ | CA9 | Q16790 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21528029 | 0.84 | CA1 (0.46) | CA2CA1CA12CA9ALDH1A1 | |
| SCHEMBL21528042 | 0.83 | CA2 (0.45) | CA2CA1CA12CA9ALDH1A1 | |
| SCHEMBL22015808 | 0.83 | CA2 (0.54) | CA2CA1CA12CA9MALT1 | |
| SCHEMBL29670329 | 0.82 | CA1 (0.49) | CA2CA1CA12CA9ALDH1A1 | |
| SCHEMBL1926110 | 0.82 | CA1 (0.52) | CA2CA1CA12CA9ALDH1A1 | |
| SCHEMBL3184725 | 0.81 | KMT2A (0.52) | CA2CA1CA12CA9 | |
| SCHEMBL22521201 | 0.80 | CA1 (0.47) | CA2CA1CA12CA9ALDH1A1 | |
| SCHEMBL22015794 | 0.79 | CA1 (0.52) | CA2CA1CA12CA9NQO2 | |
| SCHEMBL22015786 | 0.78 | CA1 (0.51) | CA2CA1CA12CA9ALDH1A1 | |
| SCHEMBL1542090 | 0.78 | L3MBTL1 (0.57) | CA2CA1CA12CA9MALT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329755-B2 | Methods for treating retroviral infections | ROCHE PALO ALTO LLC (US) | 2012-12-11 | — | — | US | disclosed |
| US-20100041648-A1 | METHODS FOR TREATING RETROVIRAL INFECTIONS | DUNN JAMES PATRICK | 2010-02-18 | — | — | US | disclosed |
| US-7625949-B2 | Methods for treating retroviral infections | ROCHE PALO ALTO LLC (US) | 2009-12-01 | — | — | US | disclosed |
| EP-1742908-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-11-11 | — | — | EP | disclosed |
| US-7166738-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2007-01-23 | — | — | US | disclosed |
| EP-1742908-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005102989-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-03 | — | — | WO | disclosed |
| US-20050239881-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2005-10-27 | — | — | US | disclosed |
| US-20050239880-A1 | Methods for treating retroviral infections | ROCHE PALO ALTO LLC | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041648-A1 | METHODS FOR TREATING RETROVIRAL INFECTIONS | CCR5, CXCR4, CCR1 | CA2 4665/4885CA1 4540/4885CA12 4403/4885 |
| US-20050239880-A1 | Methods for treating retroviral infections | CCR5, CD38, CD4 | CA2 4716/4885CA1 4673/4885CA12 4711/4885 |
| US-20050239881-A1 | Non-nucleoside reverse transcriptase inhibitors | RPP30, PNP, RTF1 | CA2 4789/4885CA1 4809/4885CA12 4875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.